Rosiglitazone and pioglitazone in the treatment of diabetes mellitus

American Journal of Health-System Pharmacy

Volumn 65, Issue 19, 2008, Pages 1846-1850

  Odom, Jessica ^a   Williamson, Bobbie ^a   Carter, Lucy ^a  

^a GREENVILLE HOSPITAL SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MURAGLITAZAR; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANEMIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; CLINICAL TRIAL; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG UTILIZATION; DYSLIPIDEMIA; EDEMA; FRACTURE; GENE INDUCTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIVER TOXICITY; MORTALITY; NOTE; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETINA MACULA EDEMA; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; STROKE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 54749117814     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070659     Document Type: Note

References (32)

1. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007; 115:114-26.
2. Grundy S, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-39.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86.
4. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998; 352:837-53. [Erratum, Lancet. 1999; 354:602.]
5. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care. 2008; 31:S12-54.
6. Abrahamson MJ. Clinical use of thiazolidinediones: recommendations. Am J Med. 2003; 115:116S-20S.
7. Hollander P, Yu D, Chou HS. Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes. Arch Intern Med. 2007; 167:1284-90.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-71. [Erratum, N Engl J Med. 2007; 357:100.]
9. Gerstein HC, Yusuf S, Holman RR et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368:1096-105. [Erratum, Lancet. 2006; 368:1770.]
10. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355:2427-43. [Erratum, N Engl J Med. 2007; 356:1387-8.]
11. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk of myocardial infarction and cardiovascular death. Ann Intern Med. 2007; 147:578-81.
12. Bloomgarden ZT. The Avandia debate. Diabetes Care. 2007; 30:2401-8.
13. Singh S, Loke YK, Furberg CD. Long term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007; 298:1189-95.
14. Home PD, Pocock SJ, Beck-Nielson H et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med. 2007; 357:28-38.
15. Dargie HJ, Hildebrandt PR, Riegger GA. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol. 2007; 49:1696-704.
16. Lipscombe LL, Gomes T, Levesque LE et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007; 298:2634-43.
17. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events): a randomized, controlled trial. Lancet. 2005; 366:1279-89.
18. Erdmann E, Charbonnel B, Wilcox RG et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007; 30:2773-8.
19. Erdmann E, Dormandy JA, Charbonnel B et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 08) study. J Am Col Cardiol. 2007; 49:1772-80.
20. Schneider CA, Ferrannini E, Defrozo R et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008; 19:182-7.
21. Lincoff A, Wolski K, Nicholls SJ et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J Am Med Assoc. 2007; 298:1180-8.
22. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007; 370:1129-36.
23. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005; 28:1547-54.
24. Martens FM, Visseren FL, Lemay J et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002; 62:1463-80.
25. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. J Am Med Assoc. 2005; 294:2581-6.
26. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised, controlled trial. Lancet. 2005; 366:1849-61. [Erratum, Lancet. 2006; 368:1415. Erratum, Lancet. 2006; 368:1420.]
27. Food and Drug Administration. FDA issues safety alert on Avandia. www.fda.gov/bbs/topics/NEWS/2007/NEW01636.html (accessed 2007 Nov 14).
28. Food and Drug Administration. Manufacturers of some diabetes drugs to strengthen warning on heart failure risk. www.fda.gov/bbs/topics/NEWS/2007/ NEW01683.html (accessed 2007 Nov 14).
29. Food and Drug Administration. FDA adds boxed warning for heart-related risks to anti-diabetes drug Avandia. www.fda.gov/bbs/topics/NEWS/2007/NEW01743. html (accessed 2007 Nov 19).
30. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008; 31:173-5. [Erratum, Diabetes Care. 2008; 51:522.]
31. Friedewald WT, Buse JB, Bigger JT et al. The action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007; 99:21i-33i.
32. Magee MF, Isley WL, BARI 2D Trial Investigators. Rationale, design, and methods for glycemic control in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Am J Cardiol. 2006; 97:20G-30G.